期刊文献+

补肾壮骨中药对糖皮质激素诱发骨质疏松大鼠的干预作用 被引量:7

原文传递
导出
摘要 目的:研究补肾壮骨中药(主要由淫羊藿、续断、补骨脂等组成)对糖皮质激素诱发的骨质疏松大鼠骨代谢、骨生物力学性能的影响。方法:30只3.5月龄雌性SD大鼠随机分为3组,每组10只,即正常对照组、模型组、补肾壮骨中药组。皮下注射甲泼尼龙(3.5 mg/kg,9 w),建立骨质疏松模型。补肾壮骨中药组造模后给予仙灵骨葆胶囊(150 mg/kg)灌胃,2/d,其他2组给予等量生理盐水,实验期9 w。9 w后测定各组大鼠骨密度(BMD)、骨代谢生化指标及骨生物力学指标等。结果:与对照组比较,模型组大鼠BMD、骨生物力学指标、血清Ca、BGP、CT水平均显著降低(P<0.05),TRACP酶活性与血清P水平无显著性变化(P>0.05);与模型组比较,补肾壮骨中药组大鼠BMD、血清Ca、BGP、CT水平均显著升高(P<0.05),但对TRACP酶活性、血清P水平无显著性影响(P>0.05)。结论:补肾壮骨中药可通过改善骨代谢生化指标及骨生物力学性能,拮抗糖皮质激素性骨质疏松大鼠的骨丢失,起到防治骨质疏松的作用。
出处 《中药材》 CAS CSCD 北大核心 2010年第4期593-595,共3页 Journal of Chinese Medicinal Materials
  • 相关文献

参考文献7

  • 1Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study [ J 1. Bone, 2006,39 ( 2 ) :253-259.
  • 2Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins,their antagonists, and the skeleton [ J ]. Endocr Rev, 2003,24 (2) : 218-235.
  • 3Griffin MG, Kimble R, Hopfer W, et al. Dual-energy x-rayabsorptiometry of the rat : accuracy, precision, and measurement of bone loss[J]. Bone Miner Res, 1993,8(7):795- 800.
  • 4Iwamoto J, Seki A, Takeda T, et al. Effects of alfacalcidol oncancellous and cortical bone mass in rats treated with glucocorticoid : a bone histomorphometry study [ J ] . Nutr Sci Vitaminol ( Tokyo ), 2007,53 ( 3 ) : 191 - 197.
  • 5中华医学会.骨质疏松和骨矿盐疾病分会糖皮质激素性骨质疏松症诊疗指南.中华全科医师杂志,2006,5(8):460-461.
  • 6刘亚伟,梅长林.糖皮质激素性骨质疏松的发病机制及治疗进展[J].国外医学(泌尿系统分册),2004,24(5):711-715. 被引量:9
  • 7刘文军,廖进民,谭小云,伦报国,赵卫东,钟世镇.椎体骨密度、体积骨密度与生物力学强度的比较[J].中国临床康复,2004,8(5):880-881. 被引量:11

二级参考文献24

  • 1中国人原发性骨质疏松症诊断标准(试行)[J].中国骨质疏松杂志,1999,5(F03):1-3. 被引量:325
  • 2Weinstein RS,Jilka RL,Parfitt AM,et al.Inhibition ofosteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes byglucocorticoids.J Clint Invest,2000,102(2):274-282.
  • 3Delany AM,Durant D,Canalis E.Glucocorticoid suppression of insulin-like growth factor I transcription in osteoblasts.Mol Endocrinol,2001,15:1781-1789.
  • 4Skrtic S,Ohlsson C.Cortisol decreases hepatocyte growth factor levels inhuman osteoblast-like cells.Calcif Tissue Int,2000,66(2):108-112.
  • 5Suda T,Takahashi N,Udagawa N,et al.Martin TJ Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families.Endocr Rev,1999,20:345-357.
  • 6Canalis E.Glucocorticoid-induced osteoporosis.Curr Opin Endocrinol Diab,2000,7:320-324.
  • 7Reid DM,Hughes RA,Laan RF,et al.Efficacy an safety of daily risedronate in the treatmentof corticosteroid-induced osteoporosis in men and women:a randomizedtrial.J Bone Miner Res,2000,15:1006-20.
  • 8American College of Rheumatiology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001 update.Arthritis Rheum,2001,44(7):1496-1503.
  • 9Loddenkemper K,Grauer A,Burmester GR,et al.Calcium,vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases.Clin Exp Rheumatol,2003,21(1):19-26.
  • 10Dougherty JA.Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.Ann Pharmacother,2002,36(3):512-6.

共引文献17

同被引文献149

引证文献7

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部